Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab + Nivolumab + Bevacizumab in Treatment-naive Advanced Hepatocellular Carcinoma
jRCT2031220213Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of relatlimab, nivolumab and bevacizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Dose-limiting toxicity (DLT) assessment and Progression-free survival (PFS) by BICR. Started Jul 2022; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2031220213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220213.